Insulet stock stabilizes after Q2 2026 revenue beat and cautious guidance

Published on 09/16/2026 at 14:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock is trading around USD 132.50 on Nasdaq as of September 14, 2026, after a 20.6 percent pullback following its Q2 2026 results and guidance, according to Yahoo Finance. The company reported Q2 2026 revenue of USD 801.7 million, up 23.5 percent year over year and roughly 1.9 percent above analyst consensus.

Flatlay Insulet – Aktienzertifikat, ISIN-Karte US45784P1012, Pod-Gerät und Stethoskop auf Marmor — Insulet Aktien-Flatlay auf weißem Marmor mit Börsenzertifikat, ISIN-Karte US45784P1012, Insulin-Pod und Stethoskop, Illustration mit AI erstellt.

Insulet stock (ISIN US45784P1012) is trading around USD 132.50 on Nasdaq as of September 14, 2026, after a 20.6 percent decline from its level before the latest quarterly results, according to Ad-hoc-news on September 15, 2026.

Q2 2026 figures: strong revenue beat with cautious outlook

As Ad-hoc-news summarized from Yahoo Finance on September 15, 2026, Insulet generated revenue of USD 801.7 million in the second quarter of 2026, an increase of 23.5 percent compared with the same quarter a year earlier, highlighting robust growth in its diabetes management business.

According to the same analysis citing Yahoo Finance, Insulet’s Q2 2026 revenue of USD 801.7 million came in about 1.9 percent above the consensus forecast from analysts, marking a clear top-line beat versus expectations and underscoring continued demand for the company’s wearable insulin delivery systems.

Share price reaction and valuation context

The Q2 2026 release was accompanied by a cautious revenue outlook for the coming quarter, which weighed on sentiment and triggered a notable share price pullback, with Insulet shares down 20.6 percent from their level before the results and quoted around USD 132.50 on Nasdaq as of September 14, 2026, based on data summarized by Ad-hoc-news.

As of the last completed trading day before September 16, 2026, Insulet stock thus reflects both the strong Q2 2026 revenue beat and the market’s concern about softer guidance, leaving the shares trading below their pre-result level and offering investors a clearer view of how expectations are being reset.

Closing price and trading details

Per the Q2 2026 performance and subsequent trading, Insulet stock closed around USD 132.50 on Nasdaq on September 14, 2026, with the move representing a 20.6 percent decline from its level before the results, in United States dollars as the primary trading currency.